Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06881836). This is a study registration, not published results. Lead sponsor: Ono Pharmaceutical Co., Ltd.. Recruitment status: COMPLETED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 260 participants (ACTUAL). Conditions: Alzheimer Disease. Interventions: DRUG: ONO-2020; DRUG: Placebo. Primary outcome measures: Incidence, severity, and type of treatment emergent adverse events (TEAEs) , From baseline up to 26 weeks; Clinically abnormal findings in Columbia Suicide Severity Rating Scale (C-SSRS) , From baseline up to 26 weeks; Change from baseline through week 26 in Alzheimer's Disease Assessment Scale-Cognitive Subscale 12 (ADAS-cog 12) score , From baseline up to 26 weeks. Brief summary: This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with Alzheimer's disease dementia.